Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody

B W Kirkham; C Pitzalis; G H Kingsley; I C Chikanza; S Sabharwal; C Barbatis; R Grahame; T Gibson; P L Amlot; G S Panayi

doi:10.1093/rheumatology/30.6.459

Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody

Br J Rheumatol. 1991 Dec;30(6):459-63. doi: 10.1093/rheumatology/30.6.459.

Authors

B W Kirkham¹, C Pitzalis, G H Kingsley, I C Chikanza, S Sabharwal, C Barbatis, R Grahame, T Gibson, P L Amlot, G S Panayi

Affiliation

¹ Rheumatology Unit, United Medical School, Guy's Hospital, London, England.

PMID: 1720991
DOI: 10.1093/rheumatology/30.6.459

Abstract

Six patients with rheumatoid arthritis were treated with a CD7 mouse monoclonal antibody, RFT2, daily for 15 days. Only two patients had a significant improvement in clinical disease activity which lasted 7-14 days. No serious adverse effects occurred although all patients developed antibodies against mouse immunoglobulin. During treatment T-lymphocyte numbers decreased and T-lymphocyte CD7 expression was absent in all but one patient.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Antigens, CD / immunology*
Antigens, CD / metabolism
Antigens, CD7
Antigens, Differentiation, T-Lymphocyte / immunology*
Antigens, Differentiation, T-Lymphocyte / metabolism
Arthritis, Rheumatoid / immunology
Arthritis, Rheumatoid / therapy*
Female
Humans
Immunosuppression Therapy
Male
Middle Aged
Synovial Membrane / immunology
T-Lymphocyte Subsets

Substances

Antibodies, Monoclonal
Antigens, CD
Antigens, CD7
Antigens, Differentiation, T-Lymphocyte